A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-30 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Novo Nordisk has also developed a genetically engineered insulin independently using a yeast process. According to a survey that the International Diabetes Federation conducted in 2002 on the access to and availability of insulin in its member countries, approximately 70% of the insulin that is currently sold in the world is recombinant, biosynthetic 'human' insulin. A majority of insulin used clinically today is produced this way, although clinical experience has provided conflicting evidence on whether these insulins are any less likely to produce an allergic reaction. Adverse reactions have been reported; these include loss of warning signs that patients may slip into a coma through hypoglycemia, convulsions, memory lapse and loss of concentration. However, the International Diabetes Federation's position statement from 2005 is very clear in stating that "there is NO overwhelming evidence to prefer one species of insulin over another" and "[modern, highly purified] animal insulins remain a perfectly acceptable alternative." Since January 2006, all insulins distributed in the US and some other countries are synthetic "human" insulins or their analogues. A special FDA importation process is required to obtain bovine or porcine derived insulin for use in the US, although there may be some remaining stocks of porcine insulin made by Lilly in 2005 or earlier, and porcine lente insulin is also sold and marketed under the brand name Vetsulin(SM) in the US for veterinary usage in the treatment of companion animals with diabetes.
Carnivory has evolved multiple times independently in plants in widely separated groups. In three species studied, Cephalotus follicularis, Nepenthes alata and Sarracenia purpurea, there has been convergence at the molecular level. Carnivorous plants secrete enzymes into the digestive fluid they produce. By studying phosphatase, glycoside hydrolase, glucanase, RNAse and chitinase enzymes as well as a pathogenesis-related protein and a thaumatin-related protein, the authors found many convergent amino acid substitutions. These changes were not at the enzymes' catalytic sites, but rather on the exposed surfaces of the proteins, where they might interact with other components of the cell or the digestive fluid. The authors also found that homologous genes in the non-carnivorous plant Arabidopsis thaliana tend to have their expression increased when the plant is stressed, leading the authors to suggest that stress-responsive proteins have often been co-opted in the repeated evolution of carnivory.
It follows that any equilibrium of this kind can be characterized either by the standard free energy change or by the equilibrium constant. In practice concentrations are more useful than activities. Activities can be calculated from concentrations if the activity coefficient are known, but this is rarely the case. Sometimes activity coefficients can be calculated using, for example, Pitzer equations or Specific ion interaction theory. Otherwise conditions must be adjusted so that activity coefficients do not vary much. For ionic solutions this is achieved by using a background ionic medium at a high concentration relative to the concentrations of the species in equilibrium. If activity coefficients are unknown they may be subsumed into the equilibrium constant, which becomes a concentration quotient. Each activity ai is assumed to be the product of a concentration, [Ai], and an activity coefficient, γi:
The body produces approximately 2.3 pounds (1.0 kg) of carbon dioxide per day per person, containing 0.63 pounds (290 g) of carbon. In humans, this carbon dioxide is carried through the venous system and is breathed out through the lungs, resulting in lower concentrations in the arteries. The carbon dioxide content of the blood is often given as the partial pressure, which is the pressure which carbon dioxide would have had if it alone occupied the volume. In humans, the blood carbon dioxide contents are shown in the adjacent table.
Sources: en.wikipedia.org
This use is of particular interest for being nontoxic and sustainable compared to other materials in moringa-growing regions where drinking water is affected by pollutants. In 2026, it was also reported that the plant's seed-based saline extract was able to remove 98% of microplastics from tap water. Moringa oleifera thus showed its potential as a sustainable alternative for microplastics removal from drinking water via in-line filtration.
=== Judiciary === Kennedy is a member of the Senate Judiciary Committee. As a member, he voted to confirm Justices Neil Gorsuch, Brett Kavanaugh, and Amy Coney Barrett. He voted against the nomination of Justice Ketanji Brown Jackson. Kennedy has defended the blue slip process for district court judges, saying that it "encourages bipartisan cooperation … The blue slip process makes our court system fairer and stronger. And that’s good for our democracy." He often asks judicial nominees basic questions about the Constitution during their confirmation process, occasionally stumping them. Kennedy has opposed the effort to add more justices to the Supreme Court, claiming it would "delegitimize" the Court. He has said he supports judges and justices who believe in "judicial restraint", adding, "Federal judges don't make law. They don't tell us what the law ought to be. They tell us what the law is." Kennedy opposed Congress establishing ethics standards for justices. He claimed such a move would violate the Constitution and called it "a crusade to undermine the United States' Supreme Court's legitimacy and the credibility of the federal judiciary." Kennedy's sharp questioning in the Judiciary Committee led to the eventual firing of former Department of Homeland Security Secretary Kristi Noem after he asked her why she had spent hundreds of millions of dollars on advertisements in which she prominently featured herself. Kennedy said he had spoken to President Trump about Noem's spending and that Trump was "mad as a mama wasp" when Noem claimed Trump had approved the spending.
== Variants == The M242 is currently in use by the United States Army, the United States Navy, the United States Marine Corps, the United States Coast Guard, the New Zealand Army, the Royal New Zealand Navy, the Norwegian Army, the Spanish Army, the Sri Lanka Navy, the Swiss Army, the Canadian Army, the Royal Canadian Navy, the Australian Army, the Royal Australian Navy, the Israeli Navy, the Philippine Navy, the Philippine Army, the Singapore Army, and the Republic of Singapore Navy as well as several others, including since 2023 the Armed Forces of Ukraine. The wide usage has resulted in several variations and modifications on the standard M242 weapon system.
Sources: en.wikipedia.org
Preotact contains recombinant human parathyroid hormone which is identical to the full-length native 84-amino acid polypeptide. Physiological actions of parathyroid hormone include stimulation of bone formation by direct effects on bone forming cells (osteoblasts) indirectly increasing the intestinal absorption of calcium and increasing the tubular reabsorption of calcium and excretion of phosphate by the kidney.
The following year, after the conclusion of New X-Men, Wolverine featured as a main character in the Astonishing X-Men (2004–2008) series, initially written by Joss Whedon and illustrated by John Cassaday. Millar wrote the "Enemy of the State" storyline, published in Wolverine #20-25 (October 2004–February 2005), in which Wolverine is brainwashed by the ninja secret society the Hand and kills numerous innocent people before returning to consciousness. As in his previous bestial state, Elektra helps him recover his humanity. In 2005, at the conclusion of the "House of M" storyline, Wolverine regained the memories he had lost or repressed. In the "Decimation" (2006) storyline, 90% of mutants lose their powers; Wolverine is among the 198 mutants who retain them. The same year, a second solo series, Wolverine: Origins, written by Daniel Way with art by Steve Dillon, ran concurrently with the Wolverine title. Wolverine: Origins delved into the ramifications of his newly remembered past and introduced Daken, his son, in issue #11 (April 2007). In 2007, Jason Aaron became the main writer for the ongoing Wolverine series. The following year, Millar and artist Steve McNiven explored a possible future for Wolverine in an eight-issue story arc entitled "Old Man Logan" that debuted with Wolverine #66 (June 2008). In Uncanny X-Men #493 (February 2008), part of the Messiah Complex storyline, Cyclops asks Wolverine to re-form and lead X-Force.
In an aqueous solution, precipitation is the "sedimentation of a solid material (a precipitate) from a liquid solution". The solid formed is called the precipitate. In case of an inorganic chemical reaction leading to precipitation, the chemical reagent causing the solid to form is called the precipitant. The liquid remaining above the precipitated or the centrifuged solid phase is also called the supernate or supernatant.
==== Baldness can be caused by emotional stress and/or sleep deprivation ==== Emotional stress has been shown to accelerate baldness in genetically susceptible individuals. Stress due to sleep deprivation in military recruits lowered testosterone levels, but it is not noted to have affected SHBG. Thus, stress due to sleep deprivation in fit males is unlikely to elevate DHT, which is one cause of male pattern baldness. Whether sleep deprivation can cause hair loss by some other mechanism is not clear.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.